Home        Sitemap        Contact us 
 
Discovery Pipeline
 
You are in: » Pipeline  » Discovery Pipeline
 
Arrien Pharmaceuticals Pipeline Overview
Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.
 
 
ARN-6039
Inhibitor of ROR-γt (Psoriasis, RA and MS)
Partner: Worldwide exclusive license granted to Boston Pharmaceuticals in 2017.

Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.

ARN-3261
Inhibitor of SIK2 (Salt Inducible Kinase 2)
To be investigated in a Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors (TNBC, DLBCL & Prostate) and AML cancers. An IND being approved to initiate the Phase 1a/1b trials beginning of Q1 2019.

The pipeline above provides the most advanced programs in the areas of Oncology, Autoimmune, CNS/Neurodegenerative diseases and stages of drug development process.

 
Copyright © 2011, Arrien Pharmaceuticals, LLC. All rights reserved.